The Wistar Institute

Today's Discoveries, Tomorrow's Cures.

Medical advances begin as scientific advances. The Wistar Institute is an independent nonprofit biomedical research institute dedicated to saving lives through science.
Our Science >
Preclinical Results Show Enhanced Antitumor Response

Dmitry Gabrilovich and his collaborators showed how an investigational drug called enitostat can be combined with an anti-PD1 monoclonal antibody.
Learn More >
Synthetic DNA Vaccine Protects Against Variety of Influenza Viruses

David Weiner and his lab developed a new method of delivering protection and addressing some of the annual challenges faced in trying to combat the spread of the seasonal flu virus.
Learn More >
First-of-its-Kind Research Apprenticeship Approved

Wistar's Biomedical Research Technician (BRT) Apprenticeship has become the first-ever registered, nontraditional apprenticeship program in biomedical research approved by the Pennsylvania Department of Labor & Industry.
Learn More >
Key RNA Editing Protein Protects Cells from Stress

The lab of Kazuko Nishikura discovered a new function of the protein ADAR1, which stops cells that have been exposed to stressors such as ultraviolet (UV) radiation from dying.
Learn More >

Connect with Wistar

Stay up-to-date with Wistar's exciting scientific discoveries and all of our upcoming events.

Wistar Shared Resources

Wistar's Shared Resources augment the power of individual labs with scientific expertise and technologies. They are available to all Wistar investigators, Wistar affiliates, and external researchers on a fee-for-service basis.

Find a Shared Resource >

Meet A Scientist

Qing Chen, M.D., Ph.D., focuses on brain metastasis, a significant clinical challenge due to its rising incidence and limited treatment options. She studies how cancer cells interact with surrounding brain cells to understand how a cancer can become metastatic.

More About Qing's Research >

Support Wistar

Your contribution directly supports Wistar scientists in their efforts to improve cancer medicine and create new vaccines.
Donate >

Giving options >

From The Wistar Wire

July 13, 2017

Wistar Science Highlights: A More Effective Flu Vaccine Design, New Drug Boosts Antitumor Effects, Awards for Melanoma Research

Recent studies from Wistar scientists have demonstrated new methods that could provide more effective ways of fighting the flu and cancer. Two scientists were also honored with awards for their work on melanoma. Read More >

July 3, 2017

Wistar Hosts Final Women & Science Event of the Season with Special Presentation About Genes and Cancer

The evening commenced with a cocktail reception before Maureen M. Murphy, Ph.D., presented on what genetic mutations mean for inherited cancer syndromes, the vital role of the p53 gene, and how cancer mutations may impact treatment decisions. Read More >

See All News

Press Releases

July 13, 2017

The Wistar Institute Appoints Two New Board Members

Wistar recently appointed John Fry and Morton Collins, Ph.D., to its Board of Trustees. Read More >

July 11, 2017

Entinostat Therapy Plays Favorable Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy

Researchers at Wistar with collaborators at Indiana University Melvin and Bren Simon Cancer Center and Syndax Pharmaceuticals, Inc., announce the results of a preclinical study demonstrating that entinostat, Syndax’s oral, Class-I histone deacetylase inhibitor, enhances the antitumor effect of PD-1 (programmed death receptor-1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs). Read More >

See All Press Releases